TWIST1 and melanoma: To determine whether the levels of ZEB1 and MITF were predictive of the patients’ response to MAPKi, we performed immunohistochemical staining for ZEB1, MITF but also TWIST1 on a cohort of 70 human BRAFV600 melanoma samples from patients whose response to the treatment was known.